ArticleEndocrine, metabolic & immune disorders drug targets2025
Comprehensive Transcriptomic and Bioinformatic Analysis of the Mechanism of Buzhong Yiqi Decoction in the Improvement of Diabetic Nephropathy.
Article in Endocrine, metabolic & immune disorders drug targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in understanding the NLRP3 inflammasome‑mediated mechanisms and therapeutic targets in diabetic nephropathy (Review).International journal of molecular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundBuzhong Yiqi decoction (BZYQ) is a classical traditional Chinese formula that has shown potential in alleviating diabetic nephropathy (DN). However, its underlying mechanisms remain unclear.
objectiveWe aimed to explore the potential targets and mechanisms of action of BZYQ in DN. MATERIALS AND
methodsA DN rat model was induced using a high-fat and high-sugar diet combined with intraperitoneal injection of streptozotocin (STZ), followed by treatment with different doses of BZYQ. Initially, the protective effects of BZYQ on renal tissue were assessed by measuring fasting blood glucose (FBG), total cholesterol (TC), triglycerides (TG), 24-hour urinary total protein (24h-UTP), urinary albumin (ALB), and serum creatinine (SCr) after administration, along with performing hematoxylin-eosin (HE) staining. Subsequently, transcriptomics and bioinformatics approaches were employed to identify the action targets and potential mechanisms of BZYQ in DN rats. Finally, real-time PCR and Western blot analyses were conducted to validate key targets and mechanisms.
resultsWe observed significant improvements in renal injury in DN rats treated with medium and high doses of BZYQ. Transcriptomic and bioinformatic analyses identified NLRP3, ASC, caspase- 1, GSDMD, IL-1β, and IL-18 as hub genes, along with differential expression of immune-related transcription factors T-bet and GATA-3 in various transcriptomes. In the validation phase, the mRNA and protein expressions of NLRP3, ASC, caspase-1, GSDMD, IL-18, IL-1β, and T-bet were significantly elevated in the DN rat model group, while GATA-3 mRNA and protein levels were significantly decreased; BZYQ was able to reverse these changes.
conclusionBZYQ has been found to have a protective effect on renal tissue damage in DN rats, potentially related to the inhibition of NLRP3 inflammasome pathway activation and the improvement of Th1/Th2 immune cell balance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.